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Table 1 The Bronchiectasis Severity Index.
Variable Points
Age (years)
<50 0
50--69 2
70--79 4
≥80 6
Body mass index (kg/m2)
<18.5 2
≥18.5 0
FEV1% predicted
>80 0
50--80 1
30--49 2
<30 3
Hospitalizations in the past 2 years
No 0
Yes 5
Exacerbation frequency in the past 12 months
0--2 0
≥3 2
MRC dyspnoea score
1--3 0
4 2
5 3
Bacterial chronic infection
Pseudomonas aeruginosa 3
Other potentially pathogenic microorganisms 1
None 0
Radiological severityredicting outcomes in bronchie
ronchiectasis is a common chronic respiratory disorder
haracterized by irreversible bronchial dilatation lead-
ng to daily productive cough and recurrent respiratory
nfections.1,2 This is a simplistic description of a multidi-
ensional disease with heterogeneous clinical course and
igniﬁcant co-morbidity.3,4 According to expert opinion,
long with vast evidence in other chronic diseases [e.g.
hronic obstructive pulmonary disease (COPD) and asthma],
ccurate severity assessment is essential to guide decision-
aking treatment and disease management.5,6
Historically evaluated based on computed tomography
CT) features,7 bronchiectasis severity assessment has been
ncreasingly recognized as an integration of many clinical,
unctional, radiological and microbiological factors.8,9 In the
ast few years, two multidimensional scoring systems, the
ronchiectasis Severity Index (BSI) and FACED have been
eveloped to integrate those fundamental factors predicting
rognosis of patients with bronchiectasis.10,11
BSI was derived from a prospective cohort including 608
atients from United Kingdom (UK) and externally validated
n independent cohorts from UK (n = 344), Belgium (n = 253)
nd Italy (n = 105).10 FACED was developed using data from
retrospective cohort of 819 patients from Spain.11 Both
cores comprise similar variables like age, Medical Research
ouncil (MRC) dyspnoea score, forced expiratory volume in
rst second (FEV1) % predicted, Pseudomonas aeruginosa
hronic infection and radiological severity. The major dif-
erence is that BSI also incorporates body mass index (BMI),
ospitalizations in the past 2 years, exacerbations in the past
2 months, and chronic infection with bacteria other than P.
eruginosa (Tables 1 and 2). BSI awards different point val-
es for each variable and FACED uses dichotomized variables
ith distinct cut-off points. Both scores classify bronchiec-
asis as mild (BSI score 0--4, FACED score 0--2), moderate (BSI
core 5--8, FACED score 3--4) or severe (BSI score ≥9, FACED
core 5--7). The scores are shown in Table 1.
Since their development, some studies have tried to com-
are and contrast the evaluation of disease severity and
he prognostic value of these two scoring systems. In the
ast edition of the Pulmonology, Costa et al.12 explored
his issue. They performed a retrospective study of 40
atients from Coimbra, Portugal to compare classiﬁcation
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531-0437/© 2018 Sociedade Portuguesa de Pneumologia. Published by
Y-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/)≥3 lobes involved or cystic bronchiectasis 1
<3 lobes involved 0f bronchiectasis severity between BSI and FACED. Three
mportant ﬁndings should be stressed. First, about one
hird of patients were classiﬁed in each severity risk cat-
gory based on BSI. In contrast, according to FACED half
Elsevier Espan˜a, S.L.U. This is an open access article under the CC
.
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Table 2 The FACED.
Variable Points
FEV1% predicted
≥50 0
<50 2
Age (years)
<70 0
≥70 2
Pseudomonas aeruginosa chronic infection
No 0
Yes 1
Radiological severity
1--2 lobes involved 0
>2 lobes involved 1
Modiﬁed MRC dyspnoea score
0--2 0
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example).21 They do, however, suggest using the BSI along-3--4 1
of patients had mild bronchiectasis, and only 12.5% had
severe bronchiectasis. Second, more than three quarters of
patients classiﬁed as severe using BSI had mild or moderate
disease by FACED, and almost half of patients with moderate
disease according to FACED had severe disease by BSI.
The key conclusion of the work by Costa et al., in our
opinion, is that BSI and FACED may contain similar varia-
bles, but are clearly measuring very different things because
there is limited correlation between them.12
Previous studies have shown similar results. The largest
study in this ﬁeld that included 1612 patients from seven
European cohorts participating in the European Bronchiec-
tasis registry project showed that BSI scored most patients as
moderate or severe (mean 6.0--9.7), while mild disease pre-
dominated according to FACED (mean 1.5--2.3).13 In a single
centre cohort study by Ellis et al.14 enrolling 74 patients,
BSI identiﬁed 31% of patients as severe versus 8% with
FACED. Moreover, 19 patients considered severe by BSI had
a mild or moderate FACED score. More recently, Rosales-
Mayor et al.15 described that, in a prospective cohort of
182 patients, severe disease accounts for 54% of all patients
with bronchiectasis based on BSI, while the majority (59%)
of patients were classiﬁed as mild or moderate by FACED.
So what are we measuring? And for whom?
The data so far suggests that, as shown by Costa and col-
leagues, the two scores measure different things. FACED was
designed to predict mortality -- a job it does very well.13--15
Most patients with bronchiectasis are at low risk of 5-year
mortality because unlike idiopathic pulmonary ﬁbrosis or
lung cancer, bronchiectasis is not a rapidly fatal disease.
As a result, most patients with bronchiectasis are classiﬁed
as ‘‘mild’’ or ‘‘moderate’’ by FACED.11--15
This is appropriate when considering the risk of mortality,
but what effect might this have on clinical practice if misin-
terpreted? A 50 year old patient having 5 exacerbations per
year, frequent hospitalizations and chronically infected with
methicillin resistant Staphylococcus aureus but with FEV1
>50% predicted for example, will score as ‘‘mild’’ accord-
ing to FACED, but no reasonable clinician would regard their
s
q
c147
urden of disease as ‘‘mild’’. FACED is relatively simple but
ts simplicity is also its weakness. A score of 5 or more
oints out of 7 is required to classify a patient as severe,
ith 2 points each awarded for age >70 and FEV1 <50% pre-
icted. This leads to unfortunate conclusions such as, for
xample, no patient under 70 can have severe bronchiecta-
is unless they also have P. aeruginosa chronic infection.11 It
as been shown by a number of authors that ‘‘mild, moder-
te and severe’’ patients according to FACED have a similar
requency of exacerbations, similar levels of quality of life
mpairment and similar symptoms making FACED an inappro-
riate tool to measure burden of disease.10--15
So in our opinion, where FACED is concerned it is more
ccurate to talk about patients being at low, moderate and
igh risk of death and not about ‘‘mild’’, ‘‘moderate’’ or
‘severe’’.
Exacerbations are the key clinical end-points in
ronchiectasis clinical trials and are a major driver of mor-
idity and mortality.16--20 We argue it is not possible to
alk about severity of bronchiectasis without talking about
xacerbations. A key question to ask all patients with
ronchiectasis is about the number and severity of exacer-
ations they have experienced. The European Respiratory
ociety guidelines based a number of their recommenda-
ions, including those for long-term antibiotic treatment on
he history of exacerbations.21
Therefore the greatest strength of the BSI is that it
laces a large degree of weight on the history of exacer-
ations. It also suffers from the limitation of including age
s a factor, and is relatively complex. The complexity is
educed by the ready availability of an online calculator at
ww.bronchiectasisseverity.com. It is much more effective
t predicting patients at high risk of future exacerbations,
orse quality of life and patients with more severe symp-
oms compared to FACED.10--15
So how should clinicians evaluate severity of disease in
aily practice for clinical decision making?
Examples of major decisions include when to use inhaled
r oral prophylactic antibiotics, how often to monitor
atients and when to refer for additional intervention such
s surgery or lung transplant assessment.21
In the authors’ opinion, the consistency of the ‘‘frequent
xacerbator’’ phenotype in bronchiectasis is such that, the
istory of exacerbations should be the major deciding fac-
or in clinical practice for the use of therapies aimed at
educing exacerbations, such as macrolides and inhaled
ntibiotics.22 The combination of frequent exacerbations
lus P. aeruginosa chronic infection, for example, is asso-
iated with poor clinical outcomes across all spectra --
ortality, hospitalizations, quality of life and future exacer-
ations. Irrespective of scoring therefore, patients should be
onsidered for antimicrobial treatment in accordance with
RS guidelines.8,9
The rigorously evidence-based ERS guidelines for
ronchiectasis published in 2017 do not recommend using
everity tools in making any treatment decisions, suggest-
ng instead to use a threshold of 3 or more exacerbations
er year to guide long-term antibiotic treatment (foride other factors such as co-morbidities and the severity of
uality of life impairment to lower this threshold in some
ases. The logic of this approach is that a patient with a
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igher BSI score and 2 exacerbations per year is at high risk
f future exacerbations and complications including hospital
dmission and so may beneﬁt from prophylactic treatment.
ACED is not mentioned in the ERS guidelines as none of
he current treatments available for bronchiectasis reduce
ortality, and therefore it is not possible to recommend
reatment, monitoring of referral based on mortality sco-
ing.
In summary, comparing BSI and FACED has clearly estab-
ished that they measure two different things. BSI is a
everity assessment tool, while FACED accurately predicts
isk of death. Clinicians should use the appropriate tool for
he appropriate context, depending on what they wish to
redict and why.
It is now more important than ever to increase awareness
f adverse prognostic features in bronchiectasis to increase
he overall quality of treatment and reduce the devastating
urden of the disease.21,22
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